{
    "nctId": "NCT05480189",
    "briefTitle": "Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study",
    "officialTitle": "Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1000,
    "primaryOutcomeMeasure": "SREs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Age \u226518 years 2. Histologically confirmed breast cancer 3. Initial diagnosis of bone metastasis by MRI or CT and treatment with zoledronic acid 4. Serum creatinine \u2264265mol/L or 3.0mg/dl 5. CrCl \u2265 30 ml/min 6. Serum Ca2+ concentration 2.0-3.0 mmonl/L 7.ECOG score \u22642 Voluntary research, informed consent\n\nExclusion Criteria:\n\n* 1. Pregnant and lactating women 2. Severe liver insufficiency (ALT and/or AST higher than 3 times the upper limit of normal) 3. Patients with osteoarthritis or other bone related diseases need bone targeted therapy 4. Patients with uncontrolled dental problems or planned jaw surgery",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}